Annual Report 2014 _  Astellas Pharma Inc.  7 Next GCL ar ea Future GCL candidates Oncology Neuroscience Immunology and Infectious diseases Diabetes mellitus (DM)  complications and Kidney diseases New therapeutic areas and Enhances  Take on the challenge of new opportunities with the innovative drug business as our core XTANDI Treatment for prostate cancer Prograf Immunosuppressant Vesicare Treatment for overactive bladder Betanis/Myrbetriq/ BETMIGA Treatment for overactive bladder